Miles De Blasio

Australia’s MRFF is sitting on billions of taxpayers’ dollars which was meant to be invested in world-leading, lifesaving health innovations.

Thanks for the invitation to speak!

Incredible lineup at #CSANZ2025! Holly Voges on stem cell heart valves, Nathan Palpant on genetic heterogeneity, Simon Foster on fibrosis targets, @milesdeblasio.bsky.social on gene therapy, and Sonia Shah on health inequities. Exciting breakthroughs!

Huge thank you to our amazing panellists for such thoughtful and inspiring conversations at today’s ECI Luncheon session 🙌 Over 50 attendees joined us to hear about the real pros & cons of doing an overseas postdoc #CSANZ2025
@fzmarques.bsky.social @dr-yktham.bsky.social @milesdeblasio.bsky.social

FYI @rebeccahritchie.bsky.social

An honour to hear Professor Bryan Williams deliver the #CSANZ2025 RT Hall Lecture. 🌟 One of the world’s leading authorities on hypertension and cardiovascular medicine, Professor Williams shared fascinating insights into targeting aldosterone to prevent and treat CVD. 🫀

🌟 Thanks to everyone who joined our ECI Networking Event!

We loved seeing such vibrant discussions on career development and research, led by the brilliant @fzmarques.bsky.social, @milesdeblasio.bsky.social and
Rebecca Ritchie.

Here’s to more collaboration and connection! 💬🔬
#CSANZ2025

Activation of AMPK by GLP-1R agonists mitigates Alzheimer-related phenotypes in transgenic mice - Nature Aging Zhang et al. identify GLP-1 receptor agonists mitigating Alzheimer’s disease-related cognitive decline and amyloid pathology in a transgenic mouse model via promoting phagocytosis and through activati...

Studies in mice reveal that AMPK activation mediates the effects of GLP-1RAs on AD, highlighting the therapeutic potential of GLP-1RAs for the treatment of #Alzheimers disease @nataging.nature.com www.nature.com/articles/s43...

Great progress being made to understand mechanisms contributing to #HFpEF

Fantastic talks from @rebeccahritchie.bsky.social & others at the #ishr2025 meeting in Nara

#cardiosky @davorpavlovic.bsky.social @monikagladka.bsky.social @jmccardiology.bsky.social @jmccplus.bsky.social

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity | NEJM Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 di...

SURMOUNT-5 Among participants with #obesity but without diabetes, treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight and waist circumference at week 72 www.nejm.org/doi/full/10....